Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DORZOLAMIDE HYDROCHLORIDE vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Adjunctive therapy with beta-blockers in patients with open-angle glaucoma or ocular hypertension
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
One drop of 2% solution in the affected eye(s) three times daily.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Dorzolamide is metabolized primarily by hepatic cytochrome P450 enzymes, specifically CYP2C9, to N-desethyl-dorzolamide. It forms N-acetylated metabolites as well as the N-desethyl metabolite. Minor renal elimination of unchanged drug occurs.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Approximately 33% bound to plasma proteins, primarily albumin.
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Wide distribution: apparent Vd is approximately 0.53 L/kg; extensive binding to carbonic anhydrase in red blood cells and tissues.
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Topical ophthalmic: systemic absorption is minimal (approximately 2-4% of administered dose reaches systemic circulation due to nasolacrimal drainage and ocular absorption).
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
No specific dose adjustment required based on Child-Pugh classification; however, use with caution in severe hepatic impairment due to potential for systemic accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients. No standard weight-based dosing guidelines available. Some sources recommend the same adult dose (one drop of 2% solution three times daily) for children aged ≥2 years; use with caution.
Not recommended for children under 18 years due to risk of respiratory depression.
No specific dose adjustment required, but elderly patients may be more susceptible to systemic effects; monitor for ocular irritation and electrolyte imbalance.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
None
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide derivative; cross-reactivity may occur. Discontinue if signs of serious hypersensitivity reactions develop.,Corneal edema and endothelial decompensation: Use with caution in patients with compromised corneas (e.g., low endothelial cell count).,Ocular effects: Transient blurred vision, burning, stinging, and superficial punctate keratitis may occur.,Potential for metabolic acidosis: Carbonic anhydrase inhibitors can cause metabolic acidosis; use with caution in patients with renal impairment or those on concomitant topiramate or acetazolamide.,Bacterial keratitis: Risk with contaminated multidose containers.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Hypersensitivity to dorzolamide hydrochloride or any component of the formulation,Severe renal impairment (creatinine clearance < 30 m L/min),Hyperchloremic acidosis
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
None known. No dietary restrictions are required with topical dorzolamide use.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (rabbit) and 20 mg/kg/day (rat). Low systemic absorption (≈4% of ocular dose) minimizes fetal exposure. FDA Pregnancy Category C. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. No specific trimester risks.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
It is not known whether dorzolamide is excreted in human milk. Systemic absorption is low (≈4%). Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not available. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for dorzolamide and potential adverse effects on the breastfed child.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
No dose adjustment is recommended. The systemic absorption of topical dorzolamide is low (≈4%) and pharmacokinetics are not expected to change significantly in pregnancy. Use the standard adult dose: one drop in the affected eye(s) three times daily.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Dorzolamide is a topical carbonic anhydrase inhibitor used for elevated intraocular pressure. It can cause metabolic acidosis due to systemic absorption, especially in patients with renal impairment. Avoid use with oral carbonic anhydrase inhibitors to prevent additive systemic effects. Monitor for corneal edema in patients with compromised corneas. The drug may cause transient blurred vision; apply pressure over the nasolacrimal duct to minimize systemic absorption.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Instill one drop in the affected eye(s) three times daily, as directed.,Wash hands before and after use. Avoid touching the dropper tip to any surface.,If using other eye drops, wait at least 5 minutes between administrations.,Do not wear contact lenses during treatment; may discolor soft contact lenses.,Report eye pain, redness, vision changes, or signs of allergy (rash, itching).,May cause temporary blurred vision; do not drive or operate machinery until vision clears.,Store at room temperature, tightly closed, and protect from light.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
"Dorzolamide, a carbonic anhydrase inhibitor used for glaucoma, may theoretically inhibit the metabolism of cobicistat, a pharmacokinetic enhancer used in HIV therapy, by competing for hepatic CYP3A4 enzymes or altering renal clearance. This interaction could lead to increased cobicistat exposure, potentiating its adverse effects such as nephrotoxicity or gastrointestinal disturbances. However, clinically relevant interactions are unlikely due to dorzolamide's limited systemic absorption following ophthalmic administration."
"Chlorthalidone, a thiazide-like diuretic, and dorzolamide, a carbonic anhydrase inhibitor, both act to reduce bicarbonate reabsorption in the kidney, leading to enhanced electrolyte excretion, particularly potassium and bicarbonate. This synergistic effect can cause additive hypokalemia and metabolic acidosis, increasing the risk of cardiac arrhythmias and renal dysfunction. Concurrent use may also potentiate hypotensive effects due to volume depletion and vasodilation."
"Concurrent administration of dorzolamide, a carbonic anhydrase inhibitor, may reduce the urinary acidification necessary for methenamine's conversion to formaldehyde, the active antibacterial agent. This alkalinization of urine pH impairs the therapeutic efficacy of methenamine in treating urinary tract infections. Clinically, this can result in suboptimal bactericidal activity and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DORZOLAMIDE HYDROCHLORIDE vs ANEXSIA 5/325, answered by our medical review team.
DORZOLAMIDE HYDROCHLORIDE is a Carbonic Anhydrase Inhibitor that works by Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DORZOLAMIDE HYDROCHLORIDE and ANEXSIA 5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DORZOLAMIDE HYDROCHLORIDE is: One drop of 2% solution in the affected eye(s) three times daily.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DORZOLAMIDE HYDROCHLORIDE and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DORZOLAMIDE HYDROCHLORIDE is classified as Category C. Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (ra. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.